JP guideline for bioequivalence studies of generic products
Guideline for Bioequivalence Studies of Generic Products
Current edition
Partial revision of March 19, 2020 (English translation)
Current edition
Partial revision of March 19, 2020 (English translation)
About this standard
Describes how to compare a generic product with the innovator product: reference product choice, study design, subjects, measurements, acceptance range, dissolution tests, reporting and dosage forms where a study is waived.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
Japan
- Bioequivalence study of an oral immediate release genericBioequivalence · Not stated
- Biowaivers and dosage forms exempt from bioequivalence studiesBioequivalence · Not stated
- Reference product and study population for generic bioequivalenceBioequivalence · Local test (some cases)
Related standards: MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.